The “Shroom Boom”

A new age in medicine is being born out of increased acceptance of individuals having the inherent right to decide what is put into their own bodies.  The “shroom boom” is here, and it could mean so many great things for the advancement of our society, including more medicinal progress, more investing opportunities, and better understanding of mental health conditions.

All of this is possible with the “shroom boom”: an increased interest in using previously banned psychedelics to treat ailments such as depression, PTSD, anxiety, and alcohol or tobacco addictions. One thing is for certain. Regardless of which side of the political aisle you walk, the attitude toward drug reform and ending the war on drugs for good is becoming a bigger issue.

It might sound almost insane to some people, but researchers have been looking into psychiatric uses of hallucinogenic drugs, especially psilocybin mushrooms (aka “magic mushrooms” or “shrooms”), since the 1950s. Psychedelic medical research was in a massive decline in the late 1960s, as psychedelic drugs like psilocybin became stigmatized due to their association with the counterculture movement. 

The use of psychedelics had all but stopped by the mid-1970s, by which time governments around the world had started to criminalize those who used these substances.  With these drugs being largely banned in the United States and elsewhere, research had been limited if not nonexistent.  But with the relaxation of the laws restricting the use of schedule 1 drugs, more studies can be conducted into how psychedelics can be used to help those who may suffer with some mental ailments.

Mushrooms have a powerful ability to affect brain chemistry, so psilocybin research is looking to improve upon the current antidepressants so many are now dependent upon.  As people open their minds to this possibility, look for “magic mushroom” to become the next major legalization drive in America!

Already, psilocybin is one of the most effective psychedelics for the treatment of conditions such as treatment-resistant depression, anxiety, PTSD and depression. With more research, we could make some major progress on helping other who suffer from these conditions with the use of psilocybin.

With this uptick in acceptance of psychedelics for the treatment of mental health concerns such as depression, companies are jumping in hoping to help find a more natural way to help. EGF Theramed Health Corp. is positioning itself at the frontier of medical science.

Psychedelic drugs are gathering support as a bona fide treatment for mental health problems, one of the most pressing and costly crises facing the modern world. As a company, EGF Theramed Health Corp. is exploring every opportunity on offer in this new area of research, forming partnerships with pioneering companies.

The company’s current focus is on the psilocybin or “magic mushroom” space, looking at methods of improving delivery systems for the compound, and creating strong intellectual property. EGF Theramed Health Corp. does not want to stop there either.  The company is exploring many other medical areas including weight loss, skin care, and heart disease. Psilocybin has become the new “it” treatment and with the help of companies such as EGF Theramed Health Corp., we can expect more research to be done on just how much it could help.

In fact, the world’s leading academic institutions are compiling a growing amount of research into the benefits of psilocybin.

Prosperous Regards,
Kenneth Ameduri
Chief Editor, CrushTheStreet.com

Disclosure/Disclaimer:
We are not brokers, investment or financial advisers, and you should not rely on the information herein as investment advice. We are a marketing company. If you are seeking personal investment advice, please contact a qualified and registered broker, investment adviser or financial adviser. You should not make any investment decisions based on our communications. You should know that Gold Standard Media LLC, owned by the same parties as Crush The Street, has been compensated three hundred thousand dollars, directly by the company, for a forty five day public awareness campaign. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT recommendations. The securities issued by the companies we profile should be considered high risk and, if you do invest, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEC filings, press releases, and risk disclosures. Information contained in this profile was provided by the company, extracted from SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it. 

Please read our full disclaimer at CrushTheStreet.com/disclaimer